Sangamo

Sangamo Therapeutics, Inc., commonly referred to as Sangamo, is a biotechnology company based in Richmond, California, United States. It specializes in genome editing and gene regulation technologies with an emphasis on developing therapies for genetic diseases and certain immune and infectious conditions.

The company was founded in 1995 and developed the zinc finger nuclease (ZFN) platform, a programmable method for editing specific DNA sequences. Sangamo also pursues strategies to modulate gene expression and delivery approaches that enable both ex vivo cell therapies and in vivo gene editing.

Sangamo’s research and development programs span a range of areas, including genetic diseases, hematologic disorders, and immune-related conditions. The company has engaged in collaborations and licensing agreements with other biopharmaceutical firms and research institutions to advance its therapeutic programs and manufacturing capabilities.

Public status and corporate activity have included its listing on the NASDAQ under the ticker SGMO. Like other companies in the gene-editing space, Sangamo has navigated the complexities of clinical development, regulatory considerations, and pipeline prioritization, reporting progress and setbacks as it advances its programs and strategic partnerships.